Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen, Pfizer Team Up on Protein Biomarker Discovery Project

NEW YORK, Oct. 8 — Ciphergen Biosystems and Pfizer said on Monday that they would collaborate on a predictive toxicology study using Ciphergen’s ProteinChip system and arrays. The study will aim to discover proteins in serum from rat models and to evaluate the relative importance and utility of such proteins as biomarkers associated with drug safety. Financial and other terms of the agreement were not disclosed. 

William Rich, president and CEO of Ciphergen, said that, if successful, he expects the collaboration to be expanded into a larger program. The work with Pfizer will be carried out in Ciphergen’s Biomarker Centers in California, Pennsylvania, and Denmark. 

The ProteinChip system enables users to rapidly identify in animal and cell culture models multiple protein biomarkers and biomarker patterns that would be predictive of likely toxicity problems. Among Ciphergen’s existing ProteinChip customers are AstraZeneca, BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, and Pharmacia. 

 

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.